Jasper Therapeutics Q3 EPS $(0.16) Misses $(0.15) Estimate
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics reported Q3 losses of $0.16 per share, missing the analyst consensus estimate of $0.15 by 6.67%. This is a 50% increase over losses of $0.32 per share from the same period last year.
November 09, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jasper Therapeutics' Q3 earnings missed analyst estimates, with losses increasing by 50% compared to the same period last year.
Jasper Therapeutics reported a larger loss than expected for Q3, missing analyst estimates. This could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100